When the Sponsor-Investigator Holds the IND for an Investigational Drug, He or She Is Responsible for Annual Reporting of Which One of the Following to FDA: The IND Report Under 21 CFR 312.33

The correct answer is the IND report — the brief annual progress report required by 21 CFR 312.33. When one person wears both hats, the annual report is not a sales projection and not a renewal application; it is a structured progress summary covering every study under the IND, due within 60 days of the IND's anniversary date. FDA has no "IND renewal" filing, which is exactly why that distractor fails.

This article walks through what the report contains, who signs it, what happens when the anniversary passes unnoticed, and how the dual sponsor-investigator role changes the safety-reporting flow that sits alongside the annual filing. It's general regulatory education, not legal advice — your IRB and a qualified regulatory professional review the specifics for your protocol.

What the annual IND report must contain under 21 CFR 312.33

The regulation lists seven content areas, and the annual report is a progress document rather than a data dump. Section (a) requires individual study information: for each study in progress or completed during the previous year, you summarize the title and protocol number, the purpose, the patient population, whether the study is completed, the number of subjects planned versus entered, the number who dropped out and why, and a brief description of any available study results. That last item trips people up — "available results" does not mean a full statistical analysis.

Section (b) covers a summary of all IND safety reports submitted during the year. Section (c) asks for a brief description of the general investigational plan for the coming year, replacing the plan from the previous annual report. If the investigator's brochure changed during the year, section (d) requires the revised brochure or a description of the changes.

Sections (e) through (g) are the ones sponsor-investigators overlook most: a description of any changes in the clinical protocol not already reported to FDA under an amendment, any changes in manufacturing or microbiological procedures that could affect drug safety, and a brief update on any outstanding business — pending FDA requests, unresolved problems, or a statement that none exist. The report is due within 60 days of the anniversary date the IND went into effect, per the opening line of 312.33.

Why "IND report" beats "adverse event summary," "marketing plan," and "renewal application"

Four options appear in the classic question bank version of this item, and each wrong answer fails for a different reason. The adverse event summary sounds plausible because safety reporting dominates IND life, but the unblinded open-label safety report is a separate submission under 21 CFR 312.32 — not the annual report. The marketing plan is a commercial document FDA does not request from an IND sponsor at all.

The IND renewal application is the most seductive distractor. An IND does not expire on a calendar schedule the way some state licenses do. It stays in effect until you withdraw it, FDA terminates it, or a 30-day review lapses without response. What keeps it alive is the annual report itself, which is why the regulation calls it a report of progress rather than a renewal.

The comparison row worth memorizing: only one of these four has a fixed annual clock. The other safety report can arrive any day of the year, and the remaining two aren't real IND filings.

The 60-day anniversary clock and what happens when you miss it

The anniversary date is not the date you started enrolling. It's the date FDA's review period ended and the IND went into effect — roughly 30 days after receipt if FDA raised no clinical hold. For a sponsor-investigator running an investigator-initiated trial at an academic center, that date is often buried in the acknowledgment letter from the initial submission, and nobody puts it on a personal calendar.

FDA's stance on late annual reports is enforcement discretion layered over a hard regulation. The agency can issue a Request for Information or a formal notice of deficiency, and repeated failure to file can trigger a clinical hold under 21 CFR 312.42, which stops enrollment and dosing until resolved. A 2019 warning letter pattern seen across academic sponsors involved missing annual reports paired with unsubmitted protocol amendments — the two failures compound.

Build the deadline backward. Note the anniversary date and set two internal checkpoints: 90 days out to start gathering subject counts from each site, and 30 days out to draft the narrative for the investigational plan. If the anniversary falls during a holiday stretch, file early rather than late. The regulation says "within 60 days," which creates a 60-day window, not a 60-day grace period after a target date.

How dual-role status changes the safety reporting you must summarize

A sponsor-investigator is one person legally filling two sets of responsibilities, and 21 CFR 312.3 defines those roles separately. The sponsor initiates and takes responsibility for the investigation; the investigator actually conducts it. When the same physician holds the IND, she writes the safety reports under 312.32 and receives them as the investigator, which means there's no separate sponsor safety desk to catch ambiguity before it reaches FDA.

That matters because section (b) of the annual report — the summary of all IND safety reports sent during the year — becomes a self-audit of your own safety judgment. If you filed three 15-day expedited reports for serious unexpected suspected adverse reactions, the annual report should list them with a one-line outcome for each. If you filed zero, say zero explicitly. A blank section reads as an omission to a reviewer, not as a clean year.

The dual role also affects the investigator's brochure obligation in section (d). At a large company, a dedicated team maintains the brochure. A solo sponsor-investigator updates it between protocols, and the annual report deadline is the natural forcing function to confirm the current edition is the one the IRB approved.

Where the annual report slots in the full IND submission calendar

Annual reporting is one item in a submission calendar that most sponsor-investigators manage without a regulatory affairs department. Mapping the full set makes the annual report's place obvious and prevents the classic mistake of treating it as the only recurring filing.

Notice what the table makes visible: the annual report is the only filing with a predictable date. Everything else fires when an event occurs. That predictability is also its trap — sponsor-investigators who are meticulous about 15-day safety reports still miss the one deadline they could have planned for a year in advance.

Assembling subject counts, dropouts, and results without overcommitting

Section (a)(2) through (a)(4) of 312.33 asks for numbers that live in different places: the planned enrollment from the protocol, the entered-to-date count from the screening and enrollment log, and the dropout count with reasons from the study coordinator's records. Pull all three from source documents rather than memory. The regulation asks for a brief description of any available results, and "available" is doing real work in that sentence.

If a study completed during the year and a final analysis exists, summarize it in two or three sentences. If data cleaning is still underway, say the study is completed and results are pending analysis — that's an accurate statement, not a dodge. What you should not do is paste in an interim statistical table that hasn't been locked; the annual report is a regulatory filing, and numbers quoted there can be compared against later publications.

Dropout reasons deserve plain language. "Lost to follow-up, 4; withdrew consent, 2; adverse event, 1" tells a reviewer what happened. A single number with no breakdown invites a follow-up question. For a sponsor-investigator at a single academic site, the coordinator's enrollment log is usually the authoritative source, and reconciling it against the IRB's continuing review numbers before drafting saves a correction later.

Common sponsor-investigator filing errors and how reviewers catch them

Three errors recur in investigator-initiated INDs, and each has a visible signature in the file. The first is filing the annual report as a narrative letter rather than a structured document organized to the seven 312.33 headings. Reviewers compare submissions against the regulation's lettering, and an unstructured letter forces them to hunt for required elements. Organize with headings (a) through (g) and the review gets faster.

The second is omitting the general investigational plan because "nothing changed." Section (c) requires the plan for the coming year in every annual report, replacing the prior year's version. Write one paragraph per planned study, even if the plan is identical to last year's — restate it.

The third is treating the annual report as a substitute for a required protocol amendment. If you changed a dose level, added a cohort, or altered eligibility criteria during the year, that change needed a 312.30 amendment at the time. The annual report's section (e) summarizes unreported changes, but summarizing a change there does not retroactively satisfy the amendment requirement. FDA has flagged this pairing in correspondence with academic sponsors, and the fix is procedural: log every protocol change in a running document so the amendment decision happens when the change happens.

Who signs, who reviews, and the small-site recordkeeping burden

The sponsor-investigator signs the annual report because she holds the sponsor's obligations. At an academic medical center, the institutional review process typically routes the draft through the office of sponsored programs or the IRB's regulatory liaison before submission, but that internal review does not transfer the legal responsibility. The signature block belongs to the person who holds the IND.

Recordkeeping runs alongside the filing. Under 21 CFR 312.57, the sponsor maintains records showing the receipt, shipment, and disposition of the investigational drug, and case histories and study records must be retained for two years after a marketing application is approved or, if the drug isn't approved, two years after the investigation is discontinued and FDA is notified. For a sponsor-investigator, that retention clock interacts with institutional data-retention policies, and the longer of the two governs.

The small-site burden is real. A solo investigator may spend eight to twelve hours assembling one annual report if subject logs are clean, and considerably more if enrollment records need reconciliation. Budgeting that time in the 90-day run-up is cheaper than a scramble in the final week, and a template organized to the seven headings cuts drafting time on every subsequent cycle.

How FDA reviews an annual report and what triggers follow-up

An annual report does not receive an approval letter. It's a notification filing that FDA reviews for signals: declining enrollment, unexplained dropouts, safety reports that suggest a pattern, or a general investigational plan that no longer matches the protocol on file. Reviewers compare the report against the IND's amendment history, so inconsistencies surface quickly.

Follow-up usually arrives as a Request for Information or as observations during a routine inspection. Under FDA's Bioresearch Monitoring program, sponsor-investigator sites are inspected against the same 312 obligations as industry sponsors, and inspectors routinely request the last two annual reports alongside the safety report log. Missing or thin annual reports become inspection observations even when the underlying study conduct was sound.

The practical takeaway for the dual-role investigator: the annual report is the one document where your safety reporting, protocol management, and enrollment records get reviewed together. Treat it as an internal audit with an external deadline, and the inspection posture takes care of itself.

FAQ

Is the annual IND report the same document as the IND safety report?

No — they're separate filings with different clocks. The safety report under 21 CFR 312.32 goes to FDA within 15 calendar days of a serious and unexpected suspected adverse reaction (7 days if fatal or life-threatening and unexpected), while the annual report under 312.33 arrives once a year. The annual report summarizes the safety reports already sent; it never substitutes for one.

What is the deadline if the IND's anniversary falls on a weekend?

The regulation's 60-day window is measured from the anniversary date, and FDA does not publish a weekend rollover rule for 312.33. File within the 60 days regardless of weekends — targeting day 45 to day 50 gives margin. If the anniversary itself is uncertain, confirm the effective date from FDA's written acknowledgment of the original IND submission.

Can an IND lapse if I skip the annual report?

An IND doesn't expire on a fixed term, so there's nothing to renew. But skipping the annual report is not harmless: FDA can issue a notice of deficiency and, for repeated noncompliance, place the study on clinical hold under 21 CFR 312.42, which halts enrollment and dosing. The IND remains technically active, yet unusable until the hold lifts.

Does the annual report need to include studies that finished years ago?

Only studies in progress or completed during the previous year belong in section (a). A trial that ended three years ago was reported in that year's annual report and doesn't reappear. However, if a long-term follow-up phase of an old study is still collecting data, that follow-up counts as in progress and should be summarized.

Who is legally responsible when a coordinator prepares the draft?

The sponsor-investigator who holds the IND signs and bears the responsibility, regardless of who drafted the document. Delegating the drafting is normal at academic sites, but the signer should verify every subject count against the enrollment log and every safety report against the submitted log before signing.

How long must I keep the records behind an annual report?

Under 21 CFR 312.57, records supporting the IND — including drug disposition records and case histories — are kept for two years after FDA approves a marketing application for the drug, or two years after the investigation is discontinued and FDA is notified if there's no approval. Institutional policy may require longer; follow whichever retention period is longer.

Does a sponsor-investigator file anything different from a company sponsor?

The form and content under 312.33 are the same for both. What differs is internal: a company routes the draft through a regulatory affairs team, while a sponsor-investigator typically routes it through an institutional review office with no transfer of legal responsibility. The FDA-facing document and its deadline are identical.

What if the general investigational plan for next year is unchanged?

Section (c) still requires the plan in every annual report, replacing the previous year's version. Restate the plan in current language, one short paragraph per planned study, and note that no substantive changes were made. Silence on section (c) is read as an incomplete filing.

This article is general educational information about FDA investigational new drug reporting requirements, not legal or regulatory advice, and it does not establish a professional relationship. Filing obligations depend on your specific IND, institutional policies, and current FDA guidance, so confirm details with a qualified regulatory professional or your institution's research compliance office before submitting. If a filing deadline has already passed, contact that office promptly rather than waiting for the next cycle.